The Impact of Pharmacokinetic-Guided Prophylaxis on Clinical Outcomes and Healthcare Resource Utilization in Hemophilia A Patients: Real-World Evidence from the CHESS II Study.

Ferri Grazzi, Enrico; Sun, Shawn X; Burke, Tom; O'Hara, Jamie

Ferri Grazzi, Enrico; Sun, Shawn X; Burke, Tom; O'Hara, Jamie.

Afiliação

Ferri Grazzi E; Health Economics and Outcomes Research, HCD Economics Ltd, Daresbury, Warrington, UK.
Sun SX; Global Evidence and Outcomes, Takeda Development Center Americas, Inc, Cambridge, MA, USA.
Burke T; Health Economics and Outcomes Research, HCD Economics Ltd, Daresbury, Warrington, UK.
O'Hara J; Department of Health and Social Care, University of Chester, Chester, UK.

J Blood Med ; 13: 505-516, 2022.

Article em En | MEDLINE | ID: mdl-36157322

Palavras-chave

CHESS II; PK-guided dosing; hemophilia A; personalized treatment; prophylaxis; recombinant factor VIII

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Qualitative_research Idioma: En Revista: J Blood Med Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Reino Unido

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google